临床试验中的遗传学 - Suppr

Suppr

超能文献

Genetics in clinical trials.

作者信息

Meschia James F, Gwinn Katrina

出版信息

Front Neurol Neurosci. 2009;25:152-157. doi: 10.1159/000209494. Epub 2009 Mar 19.

DOI:10.1159/000209494

PMID:19478516

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2789592/

Abstract

摘要

相似文献

Genetics in clinical trials.

Front Neurol Neurosci. 2009;25:152-157. doi: 10.1159/000209494. Epub 2009 Mar 19.

Clinical Trials in CNS--SMi Conference.

IDrugs. 2005 Jan;8(1):25-8.

Considerations in the design of preclinical safety evaluation programs for novel therapeutics used in neurologic diseases.

Ann N Y Acad Sci. 1995 Sep 15;765:319. doi: 10.1111/j.1749-6632.1995.tb16600.x.

What lies beneath.

Nature. 2014 Mar 20;507(7492):273. doi: 10.1038/507273a.

Mental health: Drug search on risky path.

Nature. 2014 Apr 24;508(7497):458. doi: 10.1038/508458d.

2025: the practice of neurology: back from the future.

Arch Neurol. 2001 Nov;58(11):1766-7. doi: 10.1001/archneur.58.11.1766.

Magnetic resonance imaging for surrogate outcomes and patient selection.

Front Neurol Neurosci. 2009;25:189-192. doi: 10.1159/000209499. Epub 2009 Mar 19.

The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies.

Neurology. 2009 Jun 9;72(23):2053; author reply 2053-4. doi: 10.1212/01.wnl.0000349697.25117.41.

Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle?

Lancet Neurol. 2009 Nov;8(11):975-7. doi: 10.1016/S1474-4422(09)70276-5.

Prospects for minocycline neuroprotection.

Arch Neurol. 2010 Dec;67(12):1442-8. doi: 10.1001/archneurol.2010.191. Epub 2010 Aug 9.

本文引用的文献

Multidrug resistance in epilepsy: a pharmacogenomic update.

Expert Opin Pharmacother. 2007 Jul;8(10):1441-9. doi: 10.1517/14656566.8.10.1441.

Etiology and management of refractory epilepsies.

Nat Clin Pract Neurol. 2007 Jun;3(6):320-30. doi: 10.1038/ncpneuro0521.

Effect of a US National Institutes of Health programme of clinical trials on public health and costs.

Lancet. 2006 Apr 22;367(9519):1319-27. doi: 10.1016/S0140-6736(06)68578-4.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54. doi: 10.1038/sj.tpj.6500369. Epub 2006 Jan 31.

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

Dement Geriatr Cogn Disord. 2006;21(1):33-9. doi: 10.1159/000089217. Epub 2005 Oct 25.

Shaking the tree: mapping complex disease genes with linkage disequilibrium.

Lancet. 2005 Oct 1;366(9492):1223-34. doi: 10.1016/S0140-6736(05)67485-5.

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.

Dement Geriatr Cogn Disord. 2005;20(4):254-61. doi: 10.1159/000087371. Epub 2005 Aug 9.

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.

Pharmacogenomics J. 2004;4(5):332-5. doi: 10.1038/sj.tpj.6500267.

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.

Dement Geriatr Cogn Disord. 2003;16(1):31-4. doi: 10.1159/000069990.

Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

N Engl J Med. 2003 Apr 10;348(15):1442-8. doi: 10.1056/NEJMoa021986.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Genetics in clinical trials.

Front Neurol Neurosci. 2009;25:152-157. doi: 10.1159/000209494. Epub 2009 Mar 19.

Clinical Trials in CNS--SMi Conference.

IDrugs. 2005 Jan;8(1):25-8.

Considerations in the design of preclinical safety evaluation programs for novel therapeutics used in neurologic diseases.

Ann N Y Acad Sci. 1995 Sep 15;765:319. doi: 10.1111/j.1749-6632.1995.tb16600.x.

What lies beneath.

Nature. 2014 Mar 20;507(7492):273. doi: 10.1038/507273a.

Mental health: Drug search on risky path.

Nature. 2014 Apr 24;508(7497):458. doi: 10.1038/508458d.

2025: the practice of neurology: back from the future.

Arch Neurol. 2001 Nov;58(11):1766-7. doi: 10.1001/archneur.58.11.1766.

Magnetic resonance imaging for surrogate outcomes and patient selection.

Front Neurol Neurosci. 2009;25:189-192. doi: 10.1159/000209499. Epub 2009 Mar 19.

The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies.

Neurology. 2009 Jun 9;72(23):2053; author reply 2053-4. doi: 10.1212/01.wnl.0000349697.25117.41.

Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle?

Lancet Neurol. 2009 Nov;8(11):975-7. doi: 10.1016/S1474-4422(09)70276-5.

Prospects for minocycline neuroprotection.

Arch Neurol. 2010 Dec;67(12):1442-8. doi: 10.1001/archneurol.2010.191. Epub 2010 Aug 9.

本文引用的文献

Multidrug resistance in epilepsy: a pharmacogenomic update.

Expert Opin Pharmacother. 2007 Jul;8(10):1441-9. doi: 10.1517/14656566.8.10.1441.

Etiology and management of refractory epilepsies.

Nat Clin Pract Neurol. 2007 Jun;3(6):320-30. doi: 10.1038/ncpneuro0521.

Effect of a US National Institutes of Health programme of clinical trials on public health and costs.

Lancet. 2006 Apr 22;367(9519):1319-27. doi: 10.1016/S0140-6736(06)68578-4.

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54. doi: 10.1038/sj.tpj.6500369. Epub 2006 Jan 31.

Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.

Dement Geriatr Cogn Disord. 2006;21(1):33-9. doi: 10.1159/000089217. Epub 2005 Oct 25.

Shaking the tree: mapping complex disease genes with linkage disequilibrium.

Lancet. 2005 Oct 1;366(9492):1223-34. doi: 10.1016/S0140-6736(05)67485-5.

Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.

Dement Geriatr Cogn Disord. 2005;20(4):254-61. doi: 10.1159/000087371. Epub 2005 Aug 9.

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.

Pharmacogenomics J. 2004;4(5):332-5. doi: 10.1038/sj.tpj.6500267.

Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.

Dement Geriatr Cogn Disord. 2003;16(1):31-4. doi: 10.1159/000069990.

Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

N Engl J Med. 2003 Apr 10;348(15):1442-8. doi: 10.1056/NEJMoa021986.